Latest filings (excl ownership)
ARS
2024 FY
Annual report to shareholders
23 Apr 24
DEFA14A
Additional proxy soliciting materials
23 Apr 24
DEF 14A
Definitive proxy
23 Apr 24
S-8
Registration of securities for employees
21 Mar 24
10-K
2023 FY
Annual report
21 Mar 24
8-K
Absci Reports Business Updates and Fourth Quarter and Full Year 2023 Financial and Operating Results
21 Mar 24
8-K
Absci Announces Proposed Public Offering of Common Stock
28 Feb 24
424B5
Prospectus supplement for primary offering
28 Feb 24
8-K
Results of Operations and Financial Condition
27 Feb 24
424B5
Prospectus supplement for primary offering
27 Feb 24
8-K
Absci Corporation 2024 All Rights Reserved 42ND JP Morgan Healthcare Conference
8 Jan 24
8-K
Absci and PrecisionLife Announce Strategic R&D Partnership to Jointly Develop AI-Enabled Drug Pipeline
20 Dec 23
8-K
Departure of Directors or Certain Officers
7 Dec 23
8-K
Absci Announces Collaboration with AstraZeneca to Advance AI-Driven Oncology Candidate
4 Dec 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
8-K
Absci Reports Business Updates and Third Quarter 2023 Financial and Operating Results
14 Nov 23
8-K
Other Events
5 Sep 23
8-K
Departure of Directors or Certain Officers
17 Aug 23
8-K
Absci Reports Business Updates and Second Quarter 2023 Financial and Operating Results
14 Aug 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
424B5
Prospectus supplement for primary offering
16 Jun 23
8-K
Entry into a Material Definitive Agreement
16 Jun 23
8-K
Departure of Directors or Certain Officers
6 Jun 23
UPLOAD
Letter from SEC
1 Jun 23
10-K/A
2022 FY
Annual report (amended)
30 May 23
CORRESP
Correspondence with SEC
24 May 23
10-Q
2023 Q1
Quarterly report
15 May 23
8-K
Absci Reports Business Updates and First Quarter 2023 Financial and Operating Results
15 May 23
UPLOAD
Letter from SEC
15 May 23
DEFA14A
Additional proxy soliciting materials
28 Apr 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
PRE 14A
Preliminary proxy
11 Apr 23
S-8
Registration of securities for employees
30 Mar 23
10-K
2022 FY
Annual report
30 Mar 23
8-K
Absci Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
30 Mar 23
8-K
Regulation FD Disclosure
10 Mar 23
8-K
Amendments to Articles of Incorporation or Bylaws
16 Dec 22
10-Q
2022 Q3
Quarterly report
9 Nov 22
8-K
Absci Reports Third Quarter 2022 Financial Results
9 Nov 22
Latest ownership filings
4
Sean McClain
21 Mar 24
4
Jeremy Green
5 Mar 24
SC 13D/A
Redmile Group, LLC
5 Mar 24
SC 13G/A
Phoenix Venture Partners II LP
14 Feb 24
5
Annual statement of changes in insider ownership
14 Feb 24
SC 13G
McClain Sean
13 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
4
Todd Bedrick
5 Feb 24
4
Andreas Busch
5 Feb 24
4
Zachariah Jonasson
5 Feb 24
4
Sean McClain
5 Feb 24
4
Menelas N Pangalos
4 Jan 24
3
Menelas N Pangalos
4 Jan 24
4
Zachariah Jonasson
16 Oct 23
4
Todd Bedrick
16 Oct 23
4
Andreas Busch
16 Oct 23
4
Sean McClain
16 Oct 23
4
Zachariah Jonasson
6 Sep 23
4
Amrit Nagpal
16 Jun 23
4
Jeremy Green
16 Jun 23
4
Daniel A Rabinovitsj
16 Jun 23
4
Joseph Sirosh
16 Jun 23
4
Zachariah Jonasson
16 Jun 23
4
KAREN K MCGINNIS
16 Jun 23
4
Frans Van Houten
6 Jun 23
3
Frans Van Houten
6 Jun 23
SC 13D/A
Casdin Capital, LLC
8 May 23
SC 13D/A
Casdin Capital, LLC
20 Mar 23
4
GREGORY T SCHIFFMAN
3 Mar 23
4
Sarah Korman
3 Mar 23
4
Todd Bedrick
3 Mar 23
4
Sean McClain
3 Mar 23
4
Andreas Busch
3 Mar 23
SC 13G/A
McClain Sean
14 Feb 23
SC 13G/A
Phoenix Venture Partners II LP
13 Feb 23
SC 13G
Absci / Absci ownership change
13 Feb 23
SC 13D/A
Casdin Capital, LLC
13 Feb 23
SC 13G/A
FMR LLC
9 Feb 23
4
Daniel A Rabinovitsj
2 Nov 22
3
Daniel A Rabinovitsj
2 Nov 22